Food and Drug Administration (FDA) updated the Ozempic label to include a warning for intestinal blockage after a growing number of post-marketing reports linked GLP-1 receptor agonists to severe gastrointestinal complications
As discussed in the Lipolysis and Fatty Acid Oxidation page, regulation of the rate of fatty acid entry into the mitochondria for oxidation is exerted by malonyl-CoA-mediated inhibition of CPT-1
Studies show that one year after stopping, most people regain approximately two-thirds of their lost weight unless theyve implemented substantial lifestyle changes or started alternative weight management approaches
Cell culture images were taken using a Primovert microscope (Zeiss)
Exclusivity Periods Some GLP-1 drugs are still in the exclusivity period, while others can be challenged: Liraglutide : Approved in 2010 (Victoza) and 2014 (Saxenda), its exclusivity expired in 2017, and the first generic was approved by the FDA in December 2024
Yet, as I have observed in my patients, real-world outcomes of using these weekly injectables reveal challenges: from gastrointestinal side effects and nutritional deficiencies to muscle and bone loss, adherence issues, and high treatment costs
